Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 9/20 | 0.65 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.65 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.65 |
| ▸ | MRGPRX2 | Q96LB1 | 4/20 | 0.65 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.65 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.65 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.65 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.53 |
| ▸ | ARRB1 | P49407 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11743041 | 0.91 | OPRD1 (0.65) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL28717716 | 0.89 | OPRM1 (0.62) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL16616437 | 0.88 | OPRD1 (0.68) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL7528665 | 0.88 | OPRD1 (0.63) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL15738051 | 0.87 | OPRM1 (0.69) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL11450667 | 0.87 | OPRD1 (0.69) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL1662579 | 0.87 | OPRM1 (0.69) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL15734327 | 0.86 | OPRD1 (0.68) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL28136408 | 0.86 | OPRD1 (0.68) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL27672335 | 0.85 | OPRM1 (0.67) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3634377-B1 | PHARMACEUTICAL FORMULATION | KLARIA PHARMA HOLDING AB (SE) | 2021-07-21 | — | — | EP | claimed |
| EP-3423034-B1 | ABUSE-DETERRENT PHARMACEUTICAL COMPOSITION | G L PHARMA GMBH (AT) | 2019-07-10 | — | — | EP | claimed |
| CN-109069419-A | Abuse resistant drugs composition | G.L.制药有限责任公司 | 2018-12-21 | — | — | CN | claimed |
| EP-1651184-B1 | FAST DISSOLVING ORALLY CONSUMABLE FILMS CONTAINING PHARMACEUTICALLY ACTIVE AGENTS | MCNEIL PPC INC (US) | 2013-05-22 | — | — | EP | claimed |
| EP-1617816-B1 | NANOPARTICULATE MELOXICAN FORMULATIONS | ELAN PHARMA INT LTD (IE) | 2009-05-13 | — | — | EP | claimed |
| CN-100346832-C | Pharmaceutical dosage form for transmucosal delivery | PHARMACIA CORP (US) | 2007-11-07 | — | — | CN | claimed |
| EP-1480624-B1 | PHARMACEUTICAL TABLET | PHARMACIA CORP (US) | 2006-11-29 | — | — | EP | claimed |
| EP-1471890-B1 | PHARMACEUTICAL DOSAGE FORM FOR MUCOSAL DELIVERY | PHARMACIA CORP (US) | 2006-09-27 | — | — | EP | claimed |
| EP-1608407-B1 | DISPERSIBLE FORMULATION OF AN ANTI-INFLAMMATORY AGENT | PHARMACIA CORP (US) | 2006-08-30 | — | — | EP | claimed |
| CN-1761487-A | Dispersible formulations of anti-inflammatory agents | PHARMACIA CORP (US) | 2006-04-19 | — | — | CN | claimed |
| CN-1761486-A | Dispersible pharmaceutical composition for treating mastitis and otic disorders | PHARMACIA CORP (US) | 2006-04-19 | — | — | CN | claimed |
| EP-0608893-B1 | Compositions for inhibiting the development of tolerance to and/or dependence on an additive substance | UNIV VIRGINIA COMMONWEALTH (US) | 2001-12-12 | — | — | EP | claimed |
| CN-111729161-A | Methods and devices for compound delivery | 方特慕控股第一私人有限公司 | 2020-10-02 | — | — | CN | disclosed |
| CN-105682650-B | Methods and compositions for treating withdrawal syndrome using non-sedating dexmedetomidine transdermal compositions | 帝国制药美国公司 | 2020-09-25 | — | — | CN | disclosed |
| CN-110022865-A | METHODS OF MANAGING PAIN USING DEXMEDETOMIDINE TRANSDERMAL DELIVERY DEVICES | 帝国制药美国公司 | 2019-07-16 | — | — | CN | disclosed |
| CN-109069419-A | Abuse resistant drugs composition | G.L.制药有限责任公司 | 2018-12-21 | — | — | CN | disclosed |
| CN-1121854-C | Transdermal device containing polyvinylpyrrolidone as solubility ehancer | NOVEN PHARMA (US) | 2003-09-24 | — | — | CN | disclosed |
| CN-1434713-A | Sustained-release formulation of a cyclooxygenase-2 inhibitor | PHARMACIA CORP (US) | 2003-08-06 | — | — | CN | disclosed |
| CN-1433309-A | Dual-release compositions of cyclooxygenase-2-inhibitor | PHARMNACIA CORP (US) | 2003-07-30 | — | — | CN | disclosed |
| CN-1433308-A | Cyclooxygenase-2 inhibitor compositions having rapid on set therapeutic effect | PHARMACIA CORP (US) | 2003-07-30 | — | — | CN | disclosed |